KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2025)

Historic Common Equity for Ginkgo Bioworks Holdings (DNA) over the last 7 years, with Q3 2025 value amounting to $559.8 million.

  • Ginkgo Bioworks Holdings' Common Equity fell 2984.67% to $559.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.8 million, marking a year-over-year decrease of 2984.67%. This contributed to the annual value of $716.1 million for FY2024, which is 3473.48% down from last year.
  • According to the latest figures from Q3 2025, Ginkgo Bioworks Holdings' Common Equity is $559.8 million, which was down 2984.67% from $613.0 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' 5-year Common Equity high stood at $1.7 billion for Q4 2022, and its period low was $355.8 million during Q2 2021.
  • Moreover, its 5-year median value for Common Equity was $1.1 billion (2023), whereas its average is $1.1 billion.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 34190.92% in 2022, then crashed by 4459.43% in 2024.
  • Ginkgo Bioworks Holdings' Common Equity (Quarter) stood at $1.6 billion in 2021, then grew by 10.78% to $1.7 billion in 2022, then crashed by 36.81% to $1.1 billion in 2023, then tumbled by 34.73% to $716.1 million in 2024, then decreased by 21.82% to $559.8 million in 2025.
  • Its Common Equity was $559.8 million in Q3 2025, compared to $613.0 million in Q2 2025 and $647.4 million in Q1 2025.